| Document |
Document Title |
|
WO/2022/223022A1 |
Provided are a compound represented by general formula (I), or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, an intermediate thereof, and a preparation method t...
|
|
WO/2022/224269A1 |
The present disclosure relates to co-crystals, salts and crystalline forms of Niraparib of Formula (I). More particularly, the present invention relates to novel polymorphic forms and synergistic pharmaceutical co-crystals comprising Nir...
|
|
WO/2022/224166A1 |
The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammato...
|
|
WO/2022/223039A1 |
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...
|
|
WO/2022/225941A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/223025A1 |
A heterocyclic derivative inhibitor and a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutic...
|
|
WO/2022/226133A1 |
The instant disclosure describes compounds having IL-6 modulating activity, pharmaceutical compositions and kits thereof, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.
|
|
WO/2022/226172A1 |
The present disclosure relates to compounds which increase y-oscillations in the brain. The disclosure further relates to methods of treating neurodegenerative diseases or disorders with the compounds disclosed herein.
|
|
WO/2022/222914A1 |
The present invention provides a preparation method for L-nicotine, the method can obtain L-nicotine having an optical purity of more than 99.9%, which is much higher than that of similar products in the current market. The total yield o...
|
|
WO/2022/222921A1 |
Provided are a PARP inhibitor containing a piperazine structure, a preparation method therefor and the pharmaceutical use thereof. Specifically, provided are compounds represented by general formulas (1), (2), (3), (4) and (5) and/or a p...
|
|
WO/2022/224975A1 |
Provided is a compound represented by formula (I) [in formula (I): R1 represents a substituted or unsubstituted C1-6 alkylsulfonyl group; R2 and R4 each independently represent a hydrogen atom or a substituted or unsubstituted C1-6 alkyl...
|
|
WO/2022/222995A1 |
Provided is a picolinamide compound, and specifically disclosed is a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/220599A1 |
The present invention relates to a crystal form of a sphingosine-1-phosphate receptor agonist and, more specifically, to a crystal form of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-
3,4-dihydro-naphthalen-2-ylmethyl]-pi...
|
|
WO/2022/219407A1 |
Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of Formula (I), wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered het...
|
|
WO/2022/218289A1 |
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...
|
|
WO/2022/219541A1 |
Provided herein are uses of the compounds for the treatment of various indications, including prostate cancer and Kennedy's disease.
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/220625A1 |
The present invention relates to protein degrader conjugates and a use thereof. Particularly, the present invention relates to antigen-specific binding moiety-protein degrader conjugates, and a use of the antigen-specific binding moiety-...
|
|
WO/2022/219246A1 |
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors o...
|
|
WO/2022/218296A1 |
The disclosure provides substituted fused bicyclic compounds as PARP inhibitors and the use thereof. This disclosure provides compounds represented by Formula I as below, wherein A1, A2, A3, R1, L, Cy and n are defined herein. The compou...
|
|
WO/2022/221165A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein W, R1, R2, R3, Q1 and Q2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of ...
|
|
WO/2022/220597A1 |
The present invention relates to a crystalline form of a sphingosine-1-phosphate receptor agonist and, more particularly, to a crystalline form of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-
3,4-dihydro-naphthalen-2-ylme...
|
|
WO/2022/220598A1 |
The present invention relates to a crystal form of a sphingosine-1-phosphate receptor agonist and, more specifically, to 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazole-5-ylmethoxy)
-3,4-dihydro-naphthalene-2-ylmethyl]-piperidine-4-carbo...
|
|
WO/2022/220613A1 |
The present invention relates to a novel method for preparing a compound of chemical formula 7, or a salt thereof, which is disclosed in the present specification and can be effectively used as a sphingosine-1-phosphate receptor agonist.
|
|
WO/2022/220611A1 |
The present invention relates to a novel method for preparing a compound represented by formula 5 or a salt thereof set forth in the present specification, wherein the compound or salt can be used as a sphingosine-1-phosphate receptor ag...
|
|
WO/2022/221493A1 |
Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.
|
|
WO/2022/220600A1 |
The present invention relates to a crystalline form of a sphingosine-1-phosphate receptor agonist and, more particularly, to a crystalline form of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-
3,4-dihydro-naphthalen-2-ylme...
|
|
WO/2022/220601A1 |
The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1...
|
|
WO/2022/219412A1 |
Disclosed herein, in part, is a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: (I) wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10...
|
|
WO/2022/218429A1 |
The present application relates to a bicyclic substituted aromatic carboxylic acid compound, and in particular to a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atom...
|
|
WO/2022/218247A1 |
Provided are a deuterated compound as a CDK4/6 inhibitor, a preparation method therefor, a pharmaceutical composition comprising a deuterated compound, and a use thereof. Compared with a non-deuterated reference compound, the present inv...
|
|
WO/2022/218442A1 |
Disclosed are a ring-modified proline short peptide compound and the use thereof, and specifically disclosed is a compound represented by formula (x) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/221181A1 |
The present invention relates to compounds represented by Formulae (I) to (V), or a racemate, enantiomer, diastereomer, pharmaceutically acceptable salt, solvate, hydrate, or derivative thereof, and compositions thereof. In various aspec...
|
|
WO/2022/221673A1 |
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a cereblon ligand ...
|
|
WO/2022/221526A1 |
Disclosed are compounds of formulae (I) - (IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and m...
|
|
WO/2022/221519A1 |
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatiti...
|
|
WO/2022/219546A1 |
The present application relates to Leukotriene A4 hydrolase (LTA4H) inhibitors of formula (I), for use in the treatment of various disorders.
|
|
WO/2022/221686A1 |
The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compou...
|
|
WO/2022/219146A2 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/216947A1 |
Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2022/217008A1 |
The present disclosure encompasses solid state forms of Zavegepant, in embodiments crystalline polymorphs of Zavegepant, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/215034A1 |
The present invention relates to Poly(ADP-ribose) polymerase (PARP) inhibitors, methods of preparing them, pharmaceutical compositions containing them and to their use in methods of treatment and/or prevention of PARP mediated diseases o...
|
|
WO/2022/216097A1 |
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition containing same for preventing or treating LRRK2-mediated or -related diseases or disorders; and...
|
|
WO/2022/217295A1 |
Described are compounds of formula (I), or pharmaceutically acceptable salts thereof: (I) that are useful for control of protein expression with eDHFR tags and methods of controlling protein expression with such compounds, as well as kit...
|
|
WO/2022/214701A1 |
Kinase-targeted covalent inhibitors are usually irreversibly targeting noncatalytic cysteines in the ATP- binding site. These compounds are designed by directly introducing an electrophile on a reversible-inhibitor scaffold. Our inventio...
|
|
WO/2022/216573A1 |
Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, Z, m, n, p, and q are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions compris...
|
|
WO/2022/216094A1 |
The present invention relates to: a novel compound having excellent GLP-1 agonist activity and an excellent DMPK profile, and thus useful as an agent for treating or preventing obesity or various metabolic diseases such as diabetes and h...
|
|
WO/2022/214702A1 |
Our invention relates to novel triazine compounds, containing chemical reactive groups (warheads) and behaving as reversible and irreversible covalent inhibitors. Linkers have been introduced to target a solvent exposed, distal cysteine ...
|
|
WO/2022/216975A1 |
Disclosed herein are compounds, such as compounds of Formulae (I), (II), and (III), and d3-etoricoxib, and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co- crystals, metabolites, and prodrugs thereof, and compositio...
|
|
WO/2022/216709A1 |
This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiment...
|
